Uccelli, A., Laroni, A., Brundin, L., Clanet, M., Fernandez, O., Nabavi, S. M., . . . Freedman, M. S. (2019). MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Current controlled trials in cardiovascular medicine, 20(1), 263-13. https://doi.org/10.1186/s13063-019-3346-z
Citace podle Chicago (17th ed.)Uccelli, Antonio, et al. "MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS): A Randomized, Double Blind, Cross-over Phase I/II Clinical Trial with Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis." Current Controlled Trials in Cardiovascular Medicine 20, no. 1 (2019): 263-13. https://doi.org/10.1186/s13063-019-3346-z.
Citace podle MLA (9th ed.)Uccelli, Antonio, et al. "MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS): A Randomized, Double Blind, Cross-over Phase I/II Clinical Trial with Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis." Current Controlled Trials in Cardiovascular Medicine, vol. 20, no. 1, 2019, pp. 263-13, https://doi.org/10.1186/s13063-019-3346-z.